Elicio Therapeutics

IN THE PRESS

Genetown

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

·

1 min read

Genetown

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

January 25, 2024

·

9 min read

Genetown

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

January 17, 2024

·

9 min read

Genetown

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

January 16, 2024

·

1 min read

Drug Development

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

January 11, 2024

·

6 min read

Drug Development

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

January 9, 2024

·

7 min read

Deals

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

December 22, 2023

·

4 min read

Genetown

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

December 4, 2023

·

1 min read

Business

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

November 9, 2023

·

13 min read

Drug Development

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

November 3, 2023

·

11 min read

JOBS